microRNA194过表达抑制荷瘤小鼠肝癌细胞生长的实验研究*

doi:10.3969/j.issn.1672-5069.2018.05.013

摘要/Abstract

摘要： 目的探讨microRNA194过表达对肝癌细胞生长的抑制作用及其具体作用机制。方法通过细胞转染法构建过表达microRNA194的肝癌细胞Hep3B,并将其接种于Balb/c裸鼠建立荷瘤小鼠。30只Balb/c裸鼠被随机分配为microRNA194过表达组15只和对照组15只,采用荧光定量PCR法检测Hep3B细胞和荷瘤小鼠肝癌组织microRNA194水平,采用荧光定量PCR法和Western blot法分别检测肿瘤组织胰岛素样生长因子1受体（IGF1R）水平及其蛋白表达情况。结果 Hep3B细胞和荷瘤小鼠肝癌组织microRNA194 mRNA水平分别为（2.68±0.33）和（2.33±0.38）,均显著高于对照组【分别为（1.00±0.12）和（1.00±0.16）,P<0.01】;在肝癌细胞接种第11 d、16 d和21 d时,microRNA194过表达组小鼠肝肿瘤体积分别为（0.25±0.08）、（0.31±0.11）和（0.46±0.10）mm³,均显著小于对照组【分别为（0.56±0.13）、（0.73±0.20）和（0.95±0.22）mm³,P<0.01】;在肝癌细胞接种第21 d时,microRNA194过表达组小鼠肝肿瘤质量为（0.85±0.19）g,显著轻于对照组【（1.43±0.27）g,P<0.01】;microRNA194过表达组小鼠肝肿瘤IGF1R mRNA水平和其蛋白表达量分别为（0.78±0.12）和（0.81±0.17）,均显著低于对照组【分别为（1.0±0.16）和（1.0±0.11）,P<0.01】。结论 microRNA194过表达可以抑制肝癌细胞生长,有可能是通过抑制了下游靶基因IGF1R的表达而发挥作用的。

关键词: 原发性肝癌, microRNA194, 胰岛素样生长因子1受体, 小鼠

Abstract: Objective To explore the inhibitory effect on hepatocellular carcinoma growth by microRNA194 overexpression in Balb/c nude mice,and the possible mechanism by which the microRNA194 works. Methods We constructed the hepatoma cell Hep3B with microRNA194 overexpression by cell transfection and the cells were subcutaneously inoculated into Balb/c nude mice. Then,the microRNA194 overexpression was verified in Hep3B cells and in the tumor tissues by real-time fluorescent quantitative PCR. Thirty Balb/c nude mice were randomly assigned to the microRNA194 overexpression group （n=15） and the control group （n=15）. The tumor volume was measured every 5 days and the tumor weight was measured at 21 days post-inoculation. Finally,real-time fluorescent quantitative PCR and Western bolt were performed to detect insulin-like growth factor 1 receptor （IGF1R） mRNA levels and its protein expression respectively. Results The microRNA194 levels in Hep3B cells and in tumor tissues with microRNA194 overexpression were （2.68±0.33） and （2.33±0.38）,much higher than in the control group【（1.00±0.12） and（1.00±0.16）,respectively,P<0.01】;At day 11,day 16 and day 21 post-inoculation,the tumor volume in the microRNA194 overexpression group were （0.25±0.08）,（0.31±0.11） and （0.46±0.10） mm³,much lower than in the control group 【（0.56±0.13）,（0.73±0.20） and （0.95±0.22） mm³,P<0.01】;At day 21 post-inoculation,the tumor weight in the microRNA194 overexpression group was （0.85±0.19） g,much lower than in the control group【（1.43±0.27） g,P<0.01】;the mRNA level and its protein expression of IGF1R in the microRNA194 overexpression group were（0.78±0.12） and （0.81±0.17）, much lower than in the control group 【（1.0±0.16） and （1.0±0.11）,P<0.01】. Conclusion The overexpression of microRNA194 might inhibit tumor growth by suppressing the expression of IGF1R, which needs further investigation.

Key words: Hepatocellular carcinoma, microRNA194, Insulin-like growth factor 1 receptor, Balb/c nude mice

杨学民, 李朝路, 李兆阳. microRNA194过表达抑制荷瘤小鼠肝癌细胞生长的实验研究^*[J]. 实用肝脏病杂志, 2018, 21(5): 705-708.

Yang Xuemin, Li Chaolu, Li Zhaoyang.. Inhibition of hepatocellular carcinoma growth by microRNA194 overexpression in Balb/c nude mice[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 705-708.

参考文献

[1] Han K,Zhao T,Chen X,et al.microRNA-194 suppresses osteosarcoma cell proliferation and metastasis in vitro and in vivo by targeting CDH2 and IGF1R. Int J Oncol,2014,45(4):1437-1449.
[2] 陈东风,孙文静,刘凯军,等. 非酒精性脂肪性肝病相关性肝癌的流行病学现状与发病机制. 中华肝脏病杂志,2017,25(2): 111-114.
[3] 王黎君,殷鹏,刘韫宁,等. 1990年与2013年中国人群肝癌疾病负担研究. 中华流行病学杂志,2016,37(6):758-762.
[4] Kanthaje S,Makol A,Chakraborti A.Sorafenib response in hepatocellular carcinoma:MicroRNAs as tuning forks. Hepatol Res,2018,48(1):5-14.
[5] 陈业盛,孙志为,孟春城,等. 原发性肝癌分子生物学机制和相关分子靶向药物的研究进展. 世界华人消化杂志,2015,23(6): 914-924.
[6] Quan X,Ji Y,Zhang C,et al.Circulating MiR-146a may be a potential biomarker of coronary heart disease in patients with subclinical hypothyroidism. Cell Physiol Biochem,2018,45(1): 226-236.
[7] Zhao Y,Li F,Zhang X,et al.MicroRNA-194 acts as a prognostic marker and inhibits proliferation in hepatocellular carcinoma by targeting MAP4K4. Int J Clin Exp Pathol,2015,8(10):12446-12454.
[8] Jee D,Yang JS,Park SM,et al.Dual strategies for argonaute2-mediated biogenesis of erythroid miRNAs underlie conserved requirements for slicing in mammals. Mol Cell,2018,69(2):265-278.
[9] Chen Y,Wu Z,Yuan B,et al.MicroRNA-146a-5p attenuates irradiation-induced and LPS-induced hepatic stellate cell activation and hepatocyte apoptosis through inhibition of TLR4 pathway. Cell Death Dis,2018,9(2):22.
[10] Li C,Jiang Y,Miao R,et al.MicroRNA-1271 functions as a metastasis and epithelial-mesenchymal transition inhibitor in human HCC by targeting the PTP4A1/c-Src axis. Int J Oncol,2018,52(2):536-546.
[11] Liu H,Wu H,Chen Y,et al.Serum microRNA signatures and metabolomics have high diagnostic value in hepatocellular carcinoma. Oncotarget,2017,8(65):108810-108824.
[12] Sun X,Wang M,Liu H,et al.MicroRNA-423 enhances the invasiveness of hepatocellular carcinoma via regulation of BRMS1. Am J Transl Res,2017,9(12):5576-5584.
[13] Zhou J,Zhou W,Kong F,et al.microRNA-34a overexpression inhibits cell migration and invasion via regulating SIRT1 in hepatocellular carcinoma. Oncol Lett,2017,14(6):6950-6954.[14] Yu S,Jing L,Yin XR,et al. MiR-195 suppresses the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by inhibiting YAP. Oncotarget,2017,8(59):99757-99771.
[15] Meng Z,Fu X,Chen X,et al.miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology,2010,52(6):2148-2157.
[16] Zhang Y,Wei Y,Li X,et al.microRNA-874 suppresses tumor proliferation and metastasis in hepatocellular carcinoma by targeting the DOR/EGFR/ERK pathway. Cell Death Dis,2018,9(2):130.
[17] Zhang E,Liu Q,Wang Y,et al.MicroRNA miR-147b promotes tumor growth via targeting UBE2N in hepatocellular carcinoma. Oncotarget,2017,8(69):114072-114080.
[18] Cao MQ,You AB,Zhu XD,et al.miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. J Hematol Oncol 2018,11(1):12.
[19] Sulas P,Di Tommaso L,Novello C,et al. A large set of miRNAs is dysregulated from the earliest steps of human hepatocellular carcinoma development. Am J Pathol,2017,In press.
[20] Venugopal SK,Jiang J,Kim TH,et al.Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells,and their overexpression causes decreased stellate cell activation. Am J Physiol Gastrointest Liver Physiol,2010,298(1):G101-106.

microRNA194过表达抑制荷瘤小鼠肝癌细胞生长的实验研究^*

Inhibition of hepatocellular carcinoma growth by microRNA194 overexpression in Balb/c nude mice

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.
[2]	刘杏, 赵树立, 张殿隆. 七氟烷吸入时机对肝脏部分切除术患者肝脏缺血再灌注损伤的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 728-731.
[3]	张璇, 唐小云, 唐春银, 石学魁, 王惠琦, 张晓东, 沈海萍, 杨春辉. 中药方剂赤白汤对D-氨基半乳糖诱导的急性肝衰竭小鼠肠道菌群的影响研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 478-481.
[4]	裴颖, 黄峰, 殷宏振, 郭化磊. 去甲斑蝥酸钠对肝癌异位移植瘤小鼠肠道微生态的影响初探*[J]. 实用肝脏病杂志, 2019, 22(4): 486-489.
[5]	崔发强, 李涛, 王铮, 陈青. 原发性肝癌患者外周血KRAS基因水平及其对西妥昔单克隆抗体治疗疗效的影响[J]. 实用肝脏病杂志, 2019, 22(4): 565-568.
[6]	赵晓光, 史玉洁. 应用还原型谷胱甘肽预防处理接受TACE治疗的中晚期原发性肝癌患者对肝功能的影响[J]. 实用肝脏病杂志, 2019, 22(3): 425-428.
[7]	李克田,沈明格,王凤荣,胡春荣,曹玉杰,芦鹏. 血糖水平对原发性肝癌患者¹⁸F-FDG摄取和PET/CT检查图像质量的影响研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 256-259.
[8]	郭乐乐, 张晓慧, 张向颖, 胡中杰, 任锋, 张晶. 对乙酰氨基酚诱导的急性肝损伤小鼠肝组织糖基转移酶Colgalt2表达的变化^*[J]. 实用肝脏病杂志, 2019, 22(1): 29-32.
[9]	王翠晓, 高静. 血清高尔基蛋白73、甲胎蛋白异质体3、甲胎蛋白和α-L-岩藻糖苷酶水平诊断原发性肝癌的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 113-116.
[10]	陈向, 汪宝林, 吴琛, 唐劲草, 张弛, 褚朝顺. 动脉灌注化疗栓塞联合放射粒子植入治疗原发性肝癌患者疗效及其对肝组织TRF1和TRF2表达的影响^*[J]. 实用肝脏病杂志, 2019, 22(1): 121-124.
[11]	郭晓霞, 郭琲婷, 孔祥璐. 脾切除对原发性胆汁性肝硬化小鼠肝组织纤维化影响研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 837-841.
[12]	闫书鸣, 王建国, 李泽信, 游焜, 王亮, 郭鹏威. 门冬氨酸鸟氨酸治疗肝癌切除术患者对肝脏缺血再灌注损伤的保护作用研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 932-935.
[13]	汪华, 赵亚宁. 索拉菲尼治疗进展期原发性肝癌患者有效性及安全性研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 936-939.
[14]	郭振宁. 超声造影诊断微小原发性肝癌患者临床价值研究[J]. 实用肝脏病杂志, 2018, 21(5): 741-744.
[15]	伍家彬, 谢晓海. 丙泊酚对肝部分切除术治疗的原发性肝癌患者外周血淋巴细胞亚群和血清肿瘤相关标志物水平的影响[J]. 实用肝脏病杂志, 2018, 21(5): 745-748.